Pfizer mulls US-led manufacturing amid tariff threat

Pfizer Makes $1.95 Billion Deal With U.S. For Future COVID-19 Vaccine

Jeenah Moon/Getty Images News

  • Pfizer (NYSE:PFE) CEO Albert Bourla says his company is well positioned to switch from overseas manufacturing facilities to domestic production sites if the Trump administration follows up on its plans to impose tariffs on pharmaceutical goods.
  • During a private meeting

Leave a Reply

Your email address will not be published. Required fields are marked *